Stivarga (regorafenib) is an effective drug but not one that is easily tolerable. Howard Hochster, MD, talks to us about the ReDOS study and its outcomes at the 2018 Gastrointestinal Cancers Symposium.
Advertisement
The ReDOS Study and How Using Dose Escalation of Stivarga (regorafenib) Is a Good Approach For A Hard To Tolerate Drug
By Editor